ArticleBMC research notes2025
A dataset for machine learning-based QSAR models establishment to screen beta-lactamase inhibitors using the FARM -BIOMOL chemical library.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advancements in artificial intelligence applications for the mitigation of antimicrobial resistance: challenges and opportunities.JAC-antimicrobial resistance · 2026Review
- A dataset for machine learning-based QSAR models establishment to screen beta-lactamase inhibitors using the FARM -BIOMOL chemical library.BMC research notes · 2025Article
- Utilizing machine learning-based QSAR model to overcome standalone consensus docking limitation in beta-lactamase inhibitors screening: a proof-of-concept study.BMC chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBeta-lactamase is a bacterial enzyme that deactivates beta-lactam antibiotics, and it is one of the leading causes of antibiotic resistance problems globally. In current drug discovery research, molecular simulation, like molecular docking, has been routinely integrated to virtually screen an enzyme inhibitory effect. However, a commonly known limitation of molecular docking is a low percent success rate. Previously, we reported a proof-of-concept of combining machine learning with a quantitative structure-activity relationship (QSAR) model that overcame this limitation ( https://doi.org/10.1186/s13065-024-01324-x ). Here, we presented and navigated the dataset used in our previous report, including sixty trained models (thirty for random forest and another thirty for logistic regression). DATA DESCRIPTION: This data note has three essential parts. The first part is an in vitro beta-lactamase inhibitory screening of eighty-nine bioactive molecules. The second part consisted of three molecular docking approaches (AutoDock Vina, DOCK6, and consensus docking). The last part is machine learning integrated with QSAR models. Therefore, this data note is vital for further model development to increase performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.